RxDoctor Payments Data

Tyler Patton, APRN

Family · Madison, INNPI 1750910816

Payments from drug & device makers

$1,603in general payments, 2019–2025

Across 92 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$496
  • AbbVie$408
  • Novo Nordisk$234
  • GSK$156
  • Lilly USA, LLC$57
  • Otsuka America Pharmaceutical, Inc.$54
  • plus $197 from 8 others

What the payments were for

  • Food & beverage$1,603100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,603 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$1,958
Medicare patients
73
Services billed
216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide31$49,447
MounjaroTirzepatide24$43,096
JardianceEmpagliflozin33$28,410
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$27,185
JanuviaSitagliptin Phosphate15$19,351
Nurtec OdtRimegepant Sulfate12$19,052
FarxigaDapagliflozin Propanediol15$14,960
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,221
Sumatriptan Succinate18$2,631
Theophylline ErTheophylline Anhydrous12$2,308
Albuterol Sulfate HfaAlbuterol Sulfate96$2,124
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$1,218
Ondansetron OdtOndansetron65$1,204
Levothyroxine Sodium104$1,110
Celecoxib18$900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$234$49,44731 claims
Lilly USA, LLCMounjaro$57$43,09624 claims
GSKTrelegy Ellipta$156$27,18543 claims
AstraZenecaFarxiga, Breztri Aerosphere$496$27,18134 claims
PfizerNurtec Odt$17$19,05212 claims
AbbVieSynthroid$408$37512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.

Other family in Madison

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →